Compare HAFN & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HAFN | IRTC |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.2B |
| IPO Year | 2020 | 2016 |
| Metric | HAFN | IRTC |
|---|---|---|
| Price | $8.47 | $119.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $197.92 |
| AVG Volume (30 Days) | ★ 1.1M | 659.9K |
| Earning Date | 05-14-2026 | 04-30-2026 |
| Dividend Yield | ★ 6.21% | N/A |
| EPS Growth | N/A | ★ 61.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $747,138,000.00 |
| Revenue This Year | N/A | $19.60 |
| Revenue Next Year | N/A | $15.94 |
| P/E Ratio | $11.39 | ★ N/A |
| Revenue Growth | N/A | ★ 26.24 |
| 52 Week Low | $5.17 | $100.85 |
| 52 Week High | $9.54 | $210.01 |
| Indicator | HAFN | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 63.51 | 43.63 |
| Support Level | $7.95 | $112.26 |
| Resistance Level | $8.52 | $121.88 |
| Average True Range (ATR) | 0.20 | 5.50 |
| MACD | 0.05 | -1.18 |
| Stochastic Oscillator | 85.48 | 3.23 |
Hafnia Ltd is one of the tanker owners, transporting oil, oil products and chemicals for national and international oil companies, chemical companies, as well as trading and utility companies. As owners and operators of around 200 vessels, It offers a fully integrated shipping platform, including technical management, commercial and chartering services, pool management, and a large-scale bunker procurement desk. Company manages it's business through the following reporting segments: LR2 tankers, LR1 tankers, MR tankers, Handy tankers.
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.